(2R,3S)-N-benzyl-3-methyloxirane-2-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环氧化物
• 英文名称: (2R,3S)-N-benzyl-3-methyloxirane-2-carboxamide
• 化学式: C₁₁H₁₃NO₂
• 分子量: 191.23
• InChiKey: PJRUXTVTDQGGPC-WCBMZHEXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS SPIROLACTAMES D'UN RÉCEPTEUR NMDA ET LEURS UTILISATIONS
  申请人：NAUREX INC

  公开号：WO2014120789A1

  公开（公告）日：2014-08-07

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  本发明涉及具有增强的NMDA受体活性调节效力的化合物。这样的化合物被考虑用于治疗抑郁症和相关疾病。还公开了口服制剂和其他药学上可接受的化合物输送形式，包括静脉注射制剂。
• SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
  申请人：NAUREX, INC.

  公开号：US20150376195A1

  公开（公告）日：2015-12-31

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  本发明涉及具有增强的NMDA受体活性调节功效的化合物。这样的化合物可用于治疗抑郁症和相关疾病。本发明还公开了口服制剂和其他药学上可接受的化合物给药形式，包括静脉注射制剂。
• Spiro-lactam NMDA receptor modulators and uses thereof
  申请人：Aptinyx Inc.

  公开号：US10253032B2

  公开（公告）日：2019-04-09

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  所公开的化合物在调节 NMDA 受体活性方面具有更强的效力。此类化合物可用于治疗抑郁症及相关疾病。还公开了这些化合物的口服制剂和其他药学上可接受的给药形式，包括静脉注射制剂。
• US9738650B2
  申请人：——

  公开号：US9738650B2

  公开（公告）日：2017-08-22